On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital. DeepVessel FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CTA) scans.
Coronary artery disease remains the leading cause of death worldwide in both men and women, accounting for approximately 16% of the world’s total deaths in 2019 alone. Fortunately, with proper diagnosis and management, patients suspected of coronary artery disease can be appropriately treated. Non-invasively calculating CT-FFR values using deep learning technology offers a new way of diagnosing coronary artery disease that can help to overcome the potential limitations of standalone diagnostic tests.
DeepVessel FFR is the first innovative AI software medical device introduced by the Beijing Anzhen-Keya Medical Joint Laboratory. Using deep learning algorithms, DeepVessel FFR non-invasively estimates fractional flow reserve (FFR) values at any point along the coronary artery tree from coronary CTA images to quickly assess whether interventional treatment is needed. The deep learning-based CT-FFR calculation process does not require the excess use of contrast agents or radiation exposure to the patient, and can also potentially reduce unnecessary invasive inspections to enable better diagnosis and treatment of patients with coronary artery disease.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Since 2016, Keya Medical has collaborated with more than 725 hospitals to improve diagnostics, care processes, and clinical outcomes. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.